Clematichinenoside protects blood brain barrier against ischemic stroke superimposed on systemic inflammatory challenges through up-regulating A20

Brain, Behavior, and Immunity

Volumn 51, Issue , 2016, Pages 56-69

  Han, Dan ^a   Fang, Weirong ^a   Zhang, Rui ^a   Wei, Jie ^a   Kodithuwakku, Nandani Darshika ^a   sha, Lan ^a   Ma, Wenhuan ^a   liu, Lifang ^a   Li, Fengwen ^a   Li, Yunman ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Blood brain barrier; Clematichinenoside; Ischemic stroke; NF B; Systemic inflammation; Zinc finger protein A20

Indexed keywords

CLEMATICHINENOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; NEUROPROTECTIVE AGENT; SAPONIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN A20; ANTIINFLAMMATORY AGENT; AUTACOID; DNA BINDING PROTEIN; LOC683206 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG DOSE COMPARISON; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; CELL HYPOXIA; CHEMICALLY INDUCED; DRUG EFFECTS; ENDOTHELIUM CELL; INFLAMMATION; METABOLISM; MICROVASCULATURE; SPRAGUE DAWLEY RAT; STROKE; ULTRASTRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; CELL HYPOXIA; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MICROVESSELS; NEUTROPHIL INFILTRATION; RATS; RATS, SPRAGUE-DAWLEY; SAPONINS; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939207867     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.07.025     Document Type: Article

References (46)

1. Abbitt, K.B., Rainger, G.E., Nash, G.B., Effects of fluorescent dyes on selectin and integrin-mediated stages of adhesion and migration of flowing leukocytes. J. Immunol. Methods 239:1–2 (2000), 109–119.
2. Abbott, N.J., et al. Structure and function of the blood–brain barrier. Neurobiol. Dis. 37:1 (2010), 13–25.
3. Becker, M.D., et al. In vivo fluorescence microscopy of corneal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 236:5 (1998), 390–398.
4. Belayev, L., et al. Quantitative evaluation of blood–brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739:1–2 (1996), 88–96.
5. Berger, C., et al. Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia. Exp. Neurol. 210:2 (2008), 543–548.
6. Catrysse, L., et al. A20 in inflammation and autoimmunity. Trends Immunol. 35:1 (2014), 22–31.
7. Denes, A., et al. Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain Behav. Immun. 24:5 (2010), 708–723.
8. Denes, A., Ferenczi, S., Kovacs, K.J., Systemic inflammatory challenges compromise survival after experimental stroke via augmenting brain inflammation, blood–brain barrier damage and brain oedema independently of infarct size. J. Neuroinflamm., 8, 2011, 164.
9. Dirnagl, U., Iadecola, C., Moskowitz, M.A., Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22:9 (1999), 391–397.
10. Dixit, V.M., et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J. Biol. Chem. 265:5 (1990), 2973–2978.
11. Dziedzic, T., Systemic inflammation as a therapeutic target in acute ischemic stroke. Expert Rev. Neurother. 15:5 (2015), 523–531.
12. Emsley, H.C., Hopkins, S.J., Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurol. 7:4 (2008), 341–353.
13. Emsley, H.C., Tyrrell, P.J., Inflammation and infection in clinical stroke. J. Cereb. Blood Flow Metab. 22:12 (2002), 1399–1419.
14. Eriksson, E.E., et al. Direct observations in vivo on the role of endothelial selectins and alpha(4) integrin in cytokine-induced leukocyte–endothelium interactions in the mouse aorta. Circ. Res. 86:5 (2000), 526–533.
15. Fang, W., et al. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo. J. Pharm. Pharmacol. 59:12 (2007), 1649–1655.
16. Fang, W., et al. Attenuated blood–brain barrier dysfunction by XQ-1H following ischemic stroke in hyperlipidemic rats. Mol. Neurobiol., 2014.
17. Freudenberg, M.A., et al. Role of lipopolysaccharide susceptibility in the innate immune response to Salmonella typhimurium infection: LPS, a primary target for recognition of Gram-negative bacteria. Microbes Infect. 3:14–15 (2001), 1213–1222.
18. Grilli, M., et al. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274:5291 (1996), 1383–1385.
19. Han, W., et al. Anti-arthritic effects of clematichinenoside (AR-6) on PI3K/Akt signaling pathway and TNF-alpha associated with collagen-induced arthritis. Pharm. Biol. 51:1 (2013), 13–22.
20. Hankey, G.J., Potential new risk factors for ischemic stroke: what is their potential?. Stroke 37:8 (2006), 2181–2188.
21. Heiss, E., et al. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 276:34 (2001), 32008–32015.
22. Hsu, C.C., et al. Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation. NFkB and MAPK activation. Biochem. Pharmacol. 85:3 (2013), 385–395.
23. Hutti, J.E., et al. IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol. Cell. Biol. 27:21 (2007), 7451–7461.
24. Iadecola, C., Alexander, M., Cerebral ischemia and inflammation. Curr. Opin. Neurol. 14:1 (2001), 89–94.
25. Johnston, K.C., et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 29:2 (1998), 447–453.
26. Kopp, E., Ghosh, S., Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:5174 (1994), 956–959.
27. Lee, E.G., et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289:5488 (2000), 2350–2354.
28. Longa, E.Z., et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:1 (1989), 84–91.
29. Lv, P., et al. Therapeutic neuroprotective effects of ginkgolide B on cortex and basal ganglia in a rat model of transient focal ischemia. Eur. J. Pharm. Sci. 44:3 (2011), 235–240.
30. Ma, A., Malynn, B.A., A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat. Rev. Immunol. 12:11 (2012), 774–785.
31. McColl, B.W., Rothwell, N.J., Allan, S.M., Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J. Neurosci. 28:38 (2008), 9451–9462.
32. McColl, B.W., Allan, S.M., Rothwell, N.J., Systemic infection, inflammation and acute ischemic stroke. Neuroscience 158:3 (2009), 1049–1061.
33. Mdzinarishvili, A., et al. Bilobalide prevents ischemia-induced edema formation in vitro and in vivo. Neuroscience 144:1 (2007), 217–222.
34. Medling, B.D., et al. The effect of vitamin e succinate on ischemia reperfusion injury. Hand (NY) 5:1 (2010), 60–64.
35. Pan, W., Kastin, A.J., Tumor necrosis factor and stroke: role of the blood–brain barrier. Prog. Neurobiol. 83:6 (2007), 363–374.
36. Rosenberg, G.A., Ischemic brain edema. Prog. Cardiovasc. Dis. 42:3 (1999), 209–216.
37. Sairanen, T., et al. Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. Stroke 32:8 (2001), 1750–1758.
38. Sandoval, K.E., Witt, K.A., Blood–brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis. 32:2 (2008), 200–219.
39. Siesjo, B.K., Siesjo, P., Mechanisms of secondary brain injury. Eur. J. Anaesthesiol. 13:3 (1996), 247–268.
40. Tejima, E., et al. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke 32:6 (2001), 1336–1340.
41. Wang, L., et al. Translocation of protein kinase C isoforms is involved in propofol-induced endothelial nitric oxide synthase activation. Br. J. Anaesth. 104:5 (2010), 606–612.
42. Wei, J., et al. XQ-1H suppresses neutrophils infiltration and oxidative stress induced by cerebral ischemia injury both in vivo and in vitro. Neurochem. Res., 2013.
43. Williams, A.J., Dave, J.R., Tortella, F.C., Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem. Int. 49:2 (2006), 106–112.
44. Yan, S., et al. Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB kinase/NF-kappaB pathway. Free Radic. Biol. Med. 78 (2015), 190–201.
45. Zhang, R., et al. Clematichinenoside attenuates myocardial infarction in ischemia/reperfusion injury both in vivo and in vitro. Planta Med. 79:14 (2013), 1289–1297.
46. Zheng, Z., Yenari, M.A., Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol. Res. 26:8 (2004), 884–892.